SAN DIEGO--(BUSINESS WIRE)--Jan. 3, 2017-- Illumina, Inc. (NASDAQ: ILMN), continuing its strategy to bring the power of genomics into clinical applications, today announced it has named one of the world’s top clinical genomics experts to head its clinical genomics unit. Garret Hampton, PhD, will join as Executive Vice President of Clinical Genomics for the company, starting January 9, 2017.
This Smart News Release features multimedia. View the full release here:http://www.businesswire.com/news/home/20170103005421/en/
Garret Hampton (Photo: Business Wire)
“This is a strategically important hire for Illumina,” said Francis deSouza, President and Chief Executive Officer of Illumina. “Garret has been on the front lines of oncology and brings deep expertise in clinical genomics to the leadership team, key to his new role leading our clinical genomics organization.”
Garret will be responsible for leading the clinical genomics group, including the reproductive and genetic health and oncology businesses, regulatory, clinical and medical affairs, CLIA labs, and the Chief Medical Officer’s organization. He joins Illumina from Genentech, Inc., where he was Global Head of Oncology Biomarker Development and Companion Diagnostics, co-led the Roche Personalized Medicine R&D Initiative and chaired the Roche/Foundation Medicine Joint R&D Committee. He previously held scientific and management roles at Celgene Corporation, Genomics Institute of the Novartis Research Foundation, and University of California at San Diego. Garret holds a BA in natural sciences and genetics and MA in natural sciences from Trinity College in Dublin, Ireland, and a PhD in cancer genetics from Imperial Cancer Research Fund and the University College London.
About Illumina, Inc.
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
This release contains forward-looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding the expected availability dates for new products and services and FDA submission dates and intentions for certain products and services. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in developing, manufacturing, and launching new products and services, and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170103005421/en/
Source: Illumina, Inc.
Rebecca Chambers, 858-255-5243
Eric Endicott, 858-882-6822